PACIFIC trial of durvalumab for stage III NSCLC

Bookmark and Share
Published: 9 Sep 2017
Views: 2105
Rating:
Save
Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain

Dr Paz-Ares speaks with ecancer at ESMO 2017 about the outcomes of patients with unresectable advanced lung cancer treated with anti-PD-L1 durvalumab, following chemoradiation.

He reports improved progression free survival compared to placebo, noting that a median overall survival has not yet been reached, and that these results could contribute to the eventual approval of durvalumab in this indication.

For more on this trial, watch Dr Paz-Ares present the results to the Congress here, or read our news coverage here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.